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esponsibility of Xi’Abstract Hyperlipidemia is considered to be a high lipid level in blood, can induce metabolic disorders
and dysfunctions of the body, and results in some severe complications. Therefore, hunting for some
metabolite markers and clarifying the metabolic pathways in vivo will be an important strategy in the
treatment and prevention of hyperlipidemia. In this study, a rat model of hyperlipidemia was constructed
according to histopathological data and biochemical parameters, and the metabolites of serum and urine
were analyzed by UPLC-Q-TOF/MS. Combining pattern recognition and statistical analysis, 19 candidate
biomarkers were screened and identiﬁed. These changed metabolites indicated that during the
development and progression of hyperlipidemia, energy metabolism, lipid metabolism, amino acid
metabolism and nucleotide metabolism were mainly disturbed, which are reported to be closely related to
diabetes, cardiovascular diseases, etc. This study demonstrated that a UPLC-Q-TOF/MS based
metabolomic approach is useful to proﬁle the alternation of endogenous metabolites of hyperlipidemia.
& 2014 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Hyperlipidemia is characterized by an increase in plasma total
cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol
(LDL-C) and/or a decrease in high-density lipoprotein cholesterolsity. Production and hosting by Else
2
18701201.
(Y.-F. Chai).
an Jiaotong University.(HDL-C) [1]. It was found that hyperlipidemia is a major risk factor for
atherosclerosis and cardiovascular diseases, such as hypercholesterole-
mia and hypertriglyceridemia, which are the leading causes of death in
the United States and other western countries. Emerging data establish
dyslipidemia as a signiﬁcant contributor to the development of diabetic
neuropathy, and accumulated data from several large-scale trials of
patients with type 2 diabetes also point to early dyslipidemia as a major
independent risk factor for the development of diabetic neuropathy [2].
In addition, one study suggests that hyperlipidemia and thereby
atherosclerosis are the leading causes of cardiac illness and deaths, invier B.V. All rights reserved.
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deaths than all other causes combined [3]. Therefore, it is imperative
for us to diagnose these diseases at an early stage in order to improve
the clinical outcome and reduce mortality. The progression of diseases
is mainly due to genetic determinants, environmental factors, and their
interactions [4]. Diet, as an important environmental factor, plays a
pivotal role in the development of this metabolic syndrome [5]. In
order to improve the clinical outcomes of hyperlipidemia and the
related chronic diseases mentioned above, it is necessary for us to
deeply investigate the pathophysiology of hyperlipidemia. As hyperli-
pidemia is a systemic progressive disorder, alterations of endogenous
metabolites may provide a prognostic index at the initial stage of this
disorder compared with those of the putative lipid levels at the
symptomatic stage.
Serum- or plasma-based biochemical assays and histopathological
evaluation are commonly used in the study of hyperlipidemia [6].
However, these standard approaches may be inadequate. Metabolomic,
as a sensitive and unbiased analytical method that assesses all
metabolites in biological samples, has been widely used in the
biomedical sciences [7]. This approach shows a signiﬁcant potential
for the diagnosis of human diseases [8], speciﬁcation of genetic
modiﬁcations [9], physiological evaluations [10], biomarkers screening
[11], and drug toxicity/safety assessments [12]. Metabolomics focuses
on the comprehensive measurement of small molecular weight
compounds and visualizes abnormal, disease-related physiological
states in whole samples. Moreover, it not only determines the
relationships between phenotype and metabolisms, but also identiﬁes
the key metabolites associated with a particular phenotype and
investigates the biological function and metabolic changes in the
organism [13]. Up to now, the major two analytical platforms used in
the metabolomic analysis have been nuclear magnetic resonance
(NMR) [14] and mass spectrometry (MS), which are usually coupled
to gas chromatography (GC) [4], liquid chromatography (LC), and
capillary electrophoresis (CE) [15].
In the present study, we constructed a Sprague-Dawley (SD) rat
hyperlipidemia model and applied an ultra-performance liquid chro-
matography and Q-TOF mass spectrometry (UPLC-Q-TOF/MS) based
metabolomic approach together with histopathological examination and
a biochemical assay to investigate the biochemical abnormalities
associated with hyperlipidemia in both serum and urine. The present
work, as a compensation for the results reported previously, will be
more beneﬁcial to proﬁle the alternation of endogenous metabolites of
hyperlipidemia, to dissect the underlying mechanisms related to
hyperlipidemia and the strong association with atherogenesis progres-
sion. The ﬁndings of the metabolic pathways and potential biomarkers
should be further explored for clinical prevention and treatment of
hyperlipidemia and the related chronic diseases in order to advance
the progression of amelioration in subjects with hyperlipidemia-
associated conditions and to improve the clinical outcome for these
hyperlipidemia-related conditions.2. Materials and methods
2.1. Ethics statement
All animal treatments were strictly in accordance with the National
Institutes of Health Guidelines for the Care and Use of Laboratory
Animals. Animal experiments were approved by the Administrative
Committee of the Experimental Animal Care and Use of Second
Military Medical University (SMMU, License no. 2011023).2.2. Reagents and materials
HPLC-grade methanol and acetonitrile (ACN) were purchased from
Merck (Darmstadt, Germany). Formic acid was obtained from Fluka
(Buchs, Switzerland). Ultrapure water was puriﬁed using a Milli-Q
system (Millipore, Bedford, MA, USA). The following compounds
were obtained from Shanghai Jingchun Reagent Co.: linoleic acid,
succinic acid and taurine. Hippuric acid was purchased from Larodan
AB (Malmoö, Sweden). Sphinganine and C16 Sphinganine were
purchased from Acros Organics (New Jersey, USA).
2.3. Animal study
A total of 12 adult male Sprague-Dawley rats (180720 g) obtained
from the SLAC Laboratory Animal Co., Ltd. (Shanghai, China) were
maintained under standard laboratory conditions (temperature of
21–23 1C, relative humidity of 45–65%, and 12 h/12 h light/dark
cycle) with aseptic food and tap water ad libitum. After one week of
habituation, 6 rats, selected randomly, were fed a basic diet as the
normal control group (NC), while the others were fed a high-fat diet
(HFD) for 4 weeks during the experimental period. Before the end of
the experiment, the rats were housed in metabolic cages and fasted
overnight (allowed free access to water). Rat urine was collected in
tubes. Then the rats were weighed and anesthetized with an
intraperitoneal injection of 3% sodium pentobarbital (2 mL/kg). An
abdominal incision was made to expose the liver and inferior vena
cava. Blood (3–4 mL) was withdrawn from the abdominal aorta and
collected in tubes. Serum was extracted by centrifugation at 3500 rpm
for 15 min. The serum was divided into two parts, one for the lipid
levels assay and the other for metabolomic analysis. The serum and
urine were both stored at 80 1C before UPLC-Q-TOF/MS analysis.
2.4. Histopathological examination
After being weighed, the livers were washed with saline and put in
a buffer solution of 10% formalin. Fixed tissues were processed
routinely for parafﬁn embedding, and 4 μm sections were prepared
and dyed with hematoxylin-eosin; the stained areas were viewed
under an optical microscope at 200 . The hepatic index (HI) was
estimated from the ratio of total liver weight to body weight.
2.5. Biochemical analysis
Serum was thawed and incubated at room temperature. Lipid levels,
including total cholesterol (TC), triglycerides (TG), high-density
lipoprotein-cholesterol (HDL-C) and low-density lipoprotein-choles-
terol (LDL-C), were determined using an automatic biochemical
analyzer. The arteriosclerosis index (AI) was calculated as follows:
AI¼ TCHDLC
HDLC ð1Þ
2.6. Metabolomic study
2.6.1. Extraction of the metabolites in serum and urine
The serum samples were thawed at room temperature prior to analysis.
Methanol (400 μL) was added to every 100 μL of serum. After
vigorous shaking for 1 min and incubation on ice for 10 min, the
mixture was centrifuged at 14,000 g for 15 min at 4 1C to precipitate
the protein. The urine samples were thawed at room temperature prior
to analysis. To reduce the effect of the solvent and get a good peak
Q. Wu et al.362shape, a 100 μL sample of urine was diluted with 400 μL acetonitrile
and centrifuged at 15,000 g for 10 min at 4 1C. All the clear super-
natant was transferred to an autosampler vial and kept at 4 1C. An
aliquot of 4 μL sample was made onto the column in each run. An in-
house quality control (QC) was prepared by pooling and mixing the
same volume of each sample. The QC sample was run six times prior
to the start of the analytical run to “condition” the system and analyzed
after every 3 samples to check for system stability.
2.6.2. UPLC-MS analysis
UPLC-MS analysis was performed using an Agilent 1290 Inﬁnity LC
system coupled to an Agilent 6530 Accurate-Mass Quadrupole Time-
of-Flight (Q-TOF) mass spectrometer (Agilent, USA). Chromato-
graphic separations were performed using an ACQUITY UPLC HSS
T3 column (2.1 mm 100 mm, 1.8 μm, Waters, Milford, Ireland)
maintained at 45 1C. The mobile phase consisted of 0.1% formic acid
(A) and ACN modiﬁed with 0.1% formic acid (B). The following
gradient program was used: 0% B at 0–2 min, 0%–15% B at 2–
10 min, 15%–30% B at 10–14 min, 30%–95% B at 14–17 min, 95%
B at 17–19 min, 95%–0% B at 19–20 min and followed by re-
equilibrated step of 5 min. The ﬂow rate was 400 μL/min and the
injection volume was 4 μL.
Mass spectrometry was performed using the Agilent 6530 Accurate
Mass Quadrupole Time-of-Flight (Q-TOF) mass spectrometer (Agilent,
USA), operating in both positive and negative ion modes. The capillary
voltage was 3.5 kV, the drying gas ﬂow was 11 L/min, and the gas
temperature was 350 1C. The nebulizer pressure was set at 45 psig. The
fragment voltage was set at 120 V and skimmer voltage was set at
60 V. All analyses were conducted using a mixture of 10 mM purine
(m/z 121.0508) and 2 mM hexakis phosphazinen (m/z 922.0097) as
internal standards to ensure mass accuracy and reproducibility. Data
were collected in a centroid mode and the mass range was set at m/z
50–1000 using an extended dynamic range. MS/MS analysis was
carried out to study the structure of the potential biomarkers. MS
spectra were collected at 2 spectra/s and MS/MS spectra were collected
at 0.5 spectra/s with a medium isolation window (4 m/z), and the
collision energy was 20 V.
2.6.3. Data processing and statistical analysis
Data processing used the method previously published by our group
with minor modiﬁcations [16]. The raw data in the instrument speciﬁc
format (.d) were ﬁrstly converted to common data format (.mzdata)
ﬁles by a conversion software program, in which the isotope
interferences were excluded. The program XCMS (http://metlin.
scripps.edu/download/) was used for nonlinear alignment of the dataFig. 1 Photomicrographs of hepatic tissue morphology of experimentally
shown in the liver of normal control rats (NC) and (B) large fat droplet
diet (HFD).in the time domain and automatic integration and extraction of the peak
intensities. The variables that did not present in at least 80% of the
groups were ﬁltered. The output data were imported into MATLAB 7.0
software (Math Works, Inc, USA) where data were normalized
using the summation of response of all metabolites in one sample,
in order to partially compensate for the concentration bias of
metabolites between samples and to obtain the relative intensity of
metabolites. The resulting three-dimensional matrix, including
retention time and m/z pairs, sample names, and normalized ion
intensities, was introduced to the multivariate data analysis.
Statistically signiﬁcant differences in mean values were tested
using an independent sample t-test and po0.05 was considered
statistically signiﬁcant. Prior to multivariate analysis, the resultant
data matrices were mean-centered and scaled to Pareto variance.
The data were analyzed by the orthogonal partial least squares
discriminant (OPLS-DA) method using SIMCA-P (version 11, U
metrics) which is extensively used to select the biomarkers by a
variable importance plot (VIP) [17,18]. Variables that had
signiﬁcant contributions to discrimination between groups were
preferentially considered as the potential biomarkers.3. Results
3.1. H&E staining and hepatic index
H&E staining was performed to access the fat content in the liver,
and microscopic liver tissues are shown in Fig. 1. Liver histolo-
gical examination of the NC group showed normal cell architec-
ture (Fig. 1A), while signiﬁcant morphological changes were
observed in the HFD group. Liver sections in the HFD group
showed less cells and lipid vacuolization, which are indicated with
black arrow in Fig. 1B. These results were consistent with those of
previous studies [19], and indicated that a high-fat diet accumu-
lates fat in hepatic tissue cells, which can ﬁnally cause fatty liver.
In addition, Table 1 shows signiﬁcant differences in the liver index
of the HFD group compared to the NC group.
3.2. Serum biochemical parameters
As shown in Table 1 and Fig. 2, the levels of HDL-C and LDL-C
in the serum were signiﬁcantly elevated in the HFD group
compared with the NC group. However, no signiﬁcant differences
were found between the levels of TC and TG in the serum of the
NC and HFD groups, but the contents of TC and TG were
enhanced in the HFD group. The AI was also markedly elevated inhyperlipidemic rats ( 200). The features included (A) few fat droplets
s were indicated by the arrowhead in the liver of rats fed a high-fat
Table 1 Serum lipid levels of experimental hyperlipidemic rats induced by high-fat diet.
Group TC (mM) TG (mM) HDL-C (mM) LDL-C (mM) AI HI
NC 1.4170.15 0.7870.26 1.1170.14 0.1870.08 0.2770.08 0.0370.02
HFD 1.6770.39 0.9770.28 0.9270.14n 0.5270.31n 0.8270.37n 0.0470.02nn
Values are expressed as mean 7SD, n¼6.
TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein-cholesterol; and LDL-C, low-density lipoprotein-cholesterol.
npo0.05, compared with the control group (NC).
nnpo0.01, compared with the control group (NC).
Fig. 2 Serum lipids proﬁles of the control group (NC) and the high-
fat diet group (HFD). TC, total cholesterol; TG, triglyceride; HDLC,
high-density lipoprotein cholesterol; and LDLC, low-density lipopro-
tein cholesterol. *po0.05 vs. NC.
Metabolomic proﬁling of hyperlipidemic rats 363the HFD group compared with the NC group. According to the
deﬁnition of hyperlipidemia, the rat model was successfully
constructed.3.3. Multivariate statistical analysis of metabolites
Before multivariate statistical analysis, peaks with a retention time
of less than 0.5 min (near to the dead time) were excluded due to a
high degree of ion suppression that they suffered. The datasets
from positive and negative ionization modes contained 713 and
1746 variables with the NC and HFD groups in serum, and 589
and 1239 variables with the NC and HFD groups in urine,
respectively. To determine whether the metabolite ﬁngerprints in
serum/urine differed between the NC and HFD groups in the
metabolomic approach, we constructed orthogonal partial least
squares discriminant analysis (OPLS-DA) models which have
been widely used in metabonomic studies [17,18]. In this study,
four OPLS-DA models were established and employed to identify
biomarkers which were related to hyperlipidemia in serum and
urine under the ESIþ/ESI mode, which are shown in Fig. 3.
Commonly, R2Y provides an estimate of how well the model ﬁts
the Y data, whereas Q2Y is an estimate of how well the model
predicts the Y [20]. In order to gain high predictive ability, the
values of R2Y and Q2Y should be close to 1. The related
parameters of the four OPLS-DA models are given in Fig. 3. As
Fig. 3 shows, there is a distinguished classiﬁcation between the
clustering of the NC and HFD groups. The R2Y and Q2Y were all
above 0.98 and 0.85 in four models, respectively, which indicates
that the models had good prediction characteristics.3.4. Detection and identiﬁcation of biomarker candidates
To select potential biomarkers related to hyperlipidemia, statisti-
cally signiﬁcant differences for the variables between the NC and
HFD groups were tested by an independent sample t-test.
Metabolites that differed signiﬁcantly between the NC and HFD
groups (po0.05) were identiﬁed as candidate biomarkers. Next,
the variable importance plot (VIP) reﬂecting the importance of
variables was applied to ﬁlter the important metabolites in the
model. In this study, metabolite ions with a VIP value 41.5 were
considered as potential biomarkers. Following the criteria above, a
total of 19 metabolite ions were selected as potential biomarkers
related to HFD induced hyperlipidemia. The detailed method for
compound identiﬁcation has been described in our previous work
[16,21]. A summary of biomarker candidates identiﬁed in hyperli-
pidemia rats is shown in Table 2, and the related pathway is shown
in Fig. 4.4. Discussion
In this study, a parallel metabolite proﬁling of serum and urine
based on the UPLC-Q-TOF/MS based metabolomic analysis was
applied to provide comprehensive and complementary insights
into hyperlipidemia based on the 19 selected biomarkers related to
a high fat diet induced hyperlipidemia model. The results demon-
strated that a four-week long high fat diet can markedly alter the
endogenous metabolites in SD rats by partially regulating energy
metabolism, lipid metabolism, amino acid metabolism and nucleo-
tide metabolism. The major pathways related to these metabolites
are presented in Fig. 4. In short, the combined analysis of serum
and urine is meaningful and complementary, uncovering more
comprehensive metabolomic data than either bioﬂuid alone,
providing a holistic method for determining the response of an
intact system to physical perturbation, leading to a broader view of
the metabolic network.
As we all know, succinic acid, which is localized mainly in the
mitochondria, is a vital intermediate of the TCA cycle, which is
the main pathway of glucose degradation and the primary energy
supplier for universal organisms [22]. In this study, succinic acid
was signiﬁcantly increased in the HFD group compared to the NC
group, suggesting that a high fat diet may disturb the TCA cycle
markedly and ultimately alter energy metabolism. A wealth of
evidence further supports the fact that an abnormal TCA cycle can
signiﬁcantly alter energy metabolism [23]. Our results displayed
an increased amount of succinic acid in serum, which can be
explained as a consequence of increased fatty catabolism, and it was
possible that energy metabolism was disturbed in liver mitochondria
in the process of hyperlipidemia [24].
Fig. 3 OPLS-DA score plot (top panel), loading plot (middle panel) and S-plot (bottom panel) of the UHPLC/TOF-MS spectra from the NC
group (red triangle) and HFD group (blue box). (A: serum in ESI mode; B: serum in ESIþ mode; C: urine in ESI mode; and D: urine in
ESIþ mode).
Table 2 Identiﬁcation of signiﬁcantly differential metabolites in serum/urine of hyperlipidemic rats and their related metabolic pathway.
No TR(min) Ion(m/z) Adduct Formula Identiﬁcation Trende Related pathway
1a 16.65 279.2344 [MH] C18H32O2 Linoleic acid (n)↓ Fatty acid metabolism
1b 16.63 281.2481 [MþH]þ C18H32O2 Linoleic acid (n)↓ Fatty acid metabolism
2a 16.51 303.2346 [MH] C20H32O2 8,11-Eicosadiynoic acid (n)↓ Fatty acid metabolism
3a 15.74 301.2182 [MH] C20H30O2 EPA (n)↓ Fatty acid metabolism
3b 15.72 303.2321 [MþH]þ C20H30O2 EPA (n)↓ Fatty acid metabolism
4a 9.83 453.2871 [MþCOO] C24H40O5 Cholic acid (n)↑ Cholic acid biosynthesis
5a 15.12 275.2018 [MH] C18H28O2 Stearidonic acid (n)↓ Fatty acid metabolism
6b 0.71 119.0894 [MþH]þ C4H6O4 Succinic acid (n)↑ Citrate cycle
7b 13.96 274.6561 [MþH]þ C16H35NO2 C16 Sphinganine (n)↑ Sphingolipid metabolism
8b 16.29 329.2479 [MþH]þ C22H32O2 Docosahexaenoic acid (n)↓ Fatty acid metabolism
9b 10.09 302.2149 [MþH]þ C18H39NO2 Sphinganine (n)↑ Sphingolipid metabolism
10c 5.89 178.0507 [MH] C9H9NO3 Hippuric acid (n)↓ Phenylalanine metabolism
10d 5.85 180.0656 [MþH]þ C9H9NO3 Hippuric acid (n)↓ Phenylalanine metabolism
11c 8.87 165.0557 [MH] C9H10NO3 Phenyllactic acid (n)↑ Phenylalanine metabolism
12c 0.69 124.0075 [MH] C2H7NO3S Taurine (n)↓ Taurine and hypotaurine metabolism
13c 0.77 166.0182 [MþCOO] C3H7NO2S L-Cysteine (n)↓ Taurine and hypotaurine metabolism
14c 8.88 166.0588 [MþCOO] C8H11NO3 Norepinephrine (n)↓ Tyrosine metabolism
15d 0.72 132.0981 [MþH]þ C6H13NO2 L-Isoleucine (n)↑ Valine, leucine and isoleucine degradation
16d 0.68 162.1121 [MþH]þ C7H15NO3 L-Carnitine (n)↓ Carnitine synthesis
17d 14.16 269.1387 [MþNH4]þ C10H13N5O3 DHA (n)↑ Purine metabolism
18d 0.73 259.0932 [MþH]þ C10H14N2O6 3-Methyluridine (n)↑ Pyrimidine metabolism
19d 0.85 245.1295 [MþH]þ C9H12N2O6 Uridine (n)↑ Pyrimidine metabolism
aIdentiﬁed in serum under ESI .
bIdentiﬁed in serum under ESIþ.
cIdentiﬁed in urine under ESI .
dIdentiﬁed in urine under ESIþ.
eChange trend compared with the control group. (↑): up-regulated and (↓): down-regulated.
nRepresents a statistically signiﬁcant difference (po0.05).
Q. Wu et al.364A number of previous studies suggest that lipid-based metabo-
lism is essential to many biochemistry reactions and related to
many biological functions [21]. Our results found that the levels ofﬁve unsaturated fatty acids (linoleic acid, 8,11-eicosadiynoic acid,
docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and
stearidonic acid) were signiﬁcantly down-regulated in the HFD
Fig. 4 The integrative plot of the metabolites and the relevant pathways’ changing for high-fat diet induced hyperlipidemia according to the
KEGG PATHWAY database.
Metabolomic proﬁling of hyperlipidemic rats 365group, which is indicative of enhanced peroxidation and oxidative
stress [6]. Such peroxidation and oxidative stress can further lead
to apolipoprotein B proteolysis, thus impairing the secretion of
very low-density lipoproteins (VLDL) so that exports of TG from
the liver will decrease contribution to TG accumulation in the liver
[20], which was further conﬁrmed by our liver pathological results
(Fig. 1). This lipid β-oxidation can generate large amounts of
electrons entering the mitochondrial respiratory chain to produce
excess reactive oxygen species (ROS). For example, linoleic acid,
which cannot be synthesized in vivo and has to be obtained from
the diet [25], is one of the polyunsaturated fatty acids that were
reported to be associated with atherosclerotic and inﬂammatory
diseases because they are major components of the cytoplasmic
membrane and precursor fatty acids for prostaglandins and
leukotrienes [26]. On the whole, the downgraded unsaturated fatty
acid in our study suggested that a long term high fat diet induced
hyperlipidemia altered fatty acid metabolism and induced oxida-
tive stress; however, the detailed mechanism in the process of this
lipid disorder still needs to be further investigated.
Cholic acid, a major primary bile acid, which plays an
important role in lipolysis and cholesterol catabolism, showed an
increased trend in our study. A previous study reported that bile
acids served many important physiological functions, including
cholesterol homeostasis, lipid absorption, and generation of bile
ﬂow [8]. Meanwhile, another report suggested that the rise of bile
acid caused the dysfunction of hepatic and intestinal [11]. There-
fore, the elevated cholic acids may be explained in part to that highfat diet causing the injury of liver and intestine, which was partly
supported by H&E staining (Fig. 1). Moreover, cholic acid is
synthesized in the liver and secreted in the gallbladder or intestine.
The bile acids show an important physiological function for both
absorption of nutrients and regulation of whole-body lipid
metabolism. The increased cholic acid level in the plasma of
model rats indicated that intestinal absorption of liposoluble
nutrients was disturbed in diet induced hyperlipidemic rats [27].
Of note, Guo et al. investigated the activity of hydroxymethyl
glutarate coenzyme A (HMG-CoA) reductase and microsomal
cytochrome P-450 cholesterol 7α-hydroxylase (CYP7A1) in
hyperlipidemic rats and found that the rats fed HFD showed a
slightly higher level of liver total bile acid compared with those
fed a normal diet, mainly due to up-regulation of the gene
expression of CYP7A1 in the liver of the HFD rats as compared
with those of the NC group rats [28].
Among these metabolites, sphingasine and C16 sphinganine,
two ceramide-related metabolites detected in this study, were
signiﬁcantly increased, indicating that sphingolipid metabolism
turned to be abnormal in response to hyperlipidemic. One study
reported that an obviously increased level of sphinganine in the
urine of rats may be due to the abnormal accumulation
of esteriﬁcation of cholesterol [29]. Intensive studies pointed
out the important role of sphingolipids in cell growth, cell
differentiation, cell apoptosis and vital signal transduction path-
ways [30,31]. To better understand these metabolic disorders, we
originated from some key enzymes involved in sphingolipid
Q. Wu et al.366metabolism. Sphingomyelinases (SMases) are the key enzyme
involved in the generation of ceramide and a cascade of bioactive
lipids [32]; we implicated that the up-regulating of SMases should
be one factor associated with the accumulation of sphingasine and
C16 sphinganine. However, in many cases, further study still
needs to be conducted to explore the clear mechanism of
sphingolipid-mediated etiology accompanying hyperlipidemia.
Another prominent ﬁnding in the present study is the marked
elevation levels of free nucleosides, including deoxyadenosine,
uridine, and 3-methyluridine, in the aqueous urine samples from
rats fed a high fat diet. It is indicated that lipid oversupply may
cause the degradation of nucleic acids or inhibit the synthesis of
DNA and RNA as these metabolites are the basic structural units
for nucleic acids [33]. Furthermore, a previous study supported
that the up-regulated level of uridine may be due to insufﬁcient
protein synthesis and increased compensatory RNA synthesis [34].
The study also found that amino acid metabolism was affected
in the HFD group, leading to changes in the levels of many amino
acids, including L-leucine, L-cysteine, L-carnitine, taurine, and
hippuric acid. Taurine has been reported to be the highest
abundance β-amino acid present in many tissues of humans and
animals, and processes many physiological functions such as bile
acid conjugation, antioxidation and detoxication [22]. In the
present study, the level of taurine was decreased after high fat
exposure, which could be explained in two ways: taurine acted as
an antioxidant to prevent ROS produced by oxidative stress;
moreover, taurine could bind cholic acid to improve its secretion.
Meanwhile, taurine is an end product of cysteine catabolism; large
consumption of taurine in the HFD group indirectly reﬂects the
decreased trend of cysteine in the model group [35], which could
be supported by the decline of L-cysteine acid in our results.
Hippuric acid is the glycine conjugate of benzoic acid which is
derived from phenylalanine [26]. In addition, the alteration of
urinary hippurate is frequently reported to be related to modulation
of the activity or population of gut microbiota. Therefore, high fat
exposure may have also caused changes in gut microbiota [8,33],
which needs further investigation to overcome the challenges to
the microbiome. Carnitine is a quaternary ammonium compound
that occurs both in the kidney and the liver and is transported in
the blood for use by the muscles [36]. The reason for the
alternation of the level of carnitine might be the accumulation in
serum TG levels in the model group. In our study, L-Isoleucine
was also found to be up-regulated in the HFD group and further
investigation is needed to explain this outcome.
As we all know, norepinephrine is known to promote lipid
metabolism; norepinephrine consumption would be increased
when a high lipid diet is ingested, and is supported by the present
study [25]. Epinephrine is derived from phenylalanine and
tyrosine, and it could indicate the alternation of phenylalanine
and tyrosine metabolism in the HFD group.5. Conclusion
In this study, a metabolomic approach based on UPLC-Q-TOF/MS
has been developed to proﬁle endogenous metabolic changes in
the serum and urine of HFD rats. Totally 19 sensitive biomarkers
were identiﬁed, primarily involved in energy metabolism, lipid
metabolism, amino acid metabolism and nucleotide metabolism.
By integrated histological assessment and biomedical analysis, it
was found that lipid oversupply caused signiﬁcant alternation of
endogenous metabolites, which might result in some othercomplications. This present study demonstrated that a UPLC-Q-
TOF/MS based metabolomic approach is useful to proﬁle the
alternation of endogenous metabolites of hyperlipidemia, to
achieve a “snapshot” for the mechanism of the pathogenesis of
hyperlipidemia and strong association with atherogenesis
progression.
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